Biology-Native Data Infrastructure Aims to Accelerate AI-Driven Drug Development

The core thesis here is that data architecture, not just algorithmic sophistication, is a binding constraint in AI-driven drug discovery. This is a well-recognized problem in the field but one that has received less public attention than model development. Biological data spans multiple modalities — genomic sequences, transcriptomic profiles, proteomic assays, phenotypic screens, electronic health records — each generated by different instruments, annotated with different ontologies, and stored in incompatible formats. The result is that significant ML engineering effort is spent on data wrangling rather than model training or biological insight.

"Biology-native" infrastructure, as a concept, implies designing data schemas, storage systems, and query layers that natively represent biological entities (genes, proteins, pathways, cell types, disease states) and their relationships, rather than forcing biological data into generic relational or document-store paradigms. This is adjacent to, but distinct from, existing efforts like knowledge graphs (e.g., Open Targets, the Biomedical Data Translator) and multimodal foundation models (e.g., Geneformer, scGPT). The distinction lies in emphasis: those projects focus on model architecture, whereas biology-native infrastructure focuses on the upstream data layer.

The 90% clinical failure rate cited in the source is a well-established industry figure, though it aggregates across therapeutic areas and modalities with very different failure profiles. Oncology fails at higher rates; vaccines and some rare disease programs fare better. The five-year target-to-candidate timeline is similarly a rough industry average, with significant variance by modality (small molecules vs. biologics vs. cell therapies). These statistics frame the problem accurately but should not be taken as uniform across all drug development contexts.

From a methodology standpoint, the signal here is conceptual and infrastructural rather than empirical. There is no reported dataset, model benchmark, or clinical outcome tied to this specific framing. The claim that better data infrastructure will reduce failure rates is plausible and theoretically grounded, but it has not been validated with controlled evidence in this context. Prior art — such as the federated data efforts at the FDA's Sentinel System or the UK Biobank's structured multimodal data — suggests that well-curated biological data does improve downstream analytical power, lending indirect support.

Open questions are substantial. What specific data types or biological relationships are currently most poorly represented in existing infrastructure? How does biology-native design interact with data privacy constraints, particularly for clinical and patient-level data? Will the gains be primarily in early discovery (target ID, lead optimization) or extend into translational and clinical phases? And critically, how will interoperability be maintained across institutions and platforms — a challenge that has historically undermined even well-funded data standardization efforts.

A falsifiable version of this claim would look like: organizations adopting biology-native infrastructure demonstrating statistically significant reductions in time-to-candidate or improvements in Phase II success rates compared to matched controls using conventional data systems. Without such evidence, this remains a compelling architectural argument rather than a proven intervention.